The Dash Alliance

BUILD For the 1 in every 10 people affected by a rare disease, there is a community of their friends and family who are also impacted. At The Dash Alliance, we build collaborative relationships with rare disease stakeholders to identify needs and develop impactful solutions. CONNECT We make it possible for stakeholders across the globe


Albireo is a global biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. As leader in bile acid biology, we leverage our expertise in bile acid modulation with the goal of providing hope for families by delivering potentially transformative medicines. Our parent company, Albireo Pharma,


Mirum is committed to putting the needs of patients first. We’re transforming lives devastated by rare liver disease through the development and delivery of therapies that address the urgent unmet need and fill a therapeutic void. Through continued clinical evaluation of our investigational therapies, we’re fullfiling our promise to the community. Left untreated, these diseases